TRILUMINATE Pivotal - 2-year update EuroPCR 25, presented by G. Singh
The TRILUMINATE Pivotal trial demonstrated that TriClip™ TEER was superior to medical therapy alone at reducing Heart Failure Hospitalization (HFH) risk at 2 years, while confirming its exceptional safety and quality of life improvement
LEARN MORE:
Related Resources
bRIGHT 2-year real-world outcomes
Prognosis of TR after MitraClip for MR
Poster: Primary MR in the Very Elderly
PCR LV 2021: Navitor™ Looking ahead
EXPAND Study: Data overview
ESC 2021: HF & VHD Guidelines
PCR LV 2021: Navitor™ Live-in-a-box
Navitor Valve in small aortic annuli
ACC 2023: COAPT™ trial
TRENDING TOPICS
Prognosis of TR after MitraClip for MR
Poster: Primary MR in the Very Elderly
bRIGHT 2-year real-world outcomes
